eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2021-12-30 14 4 1781 1790 10.13005/bpj/2277 41801 article Dalia Zaafar 1 Toka Elemary 2 Yara Abdel Hady 2 Aya Essawy 3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, MTI University, Cairo, Egypt. Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Department of Clinical Pharmacy, Faculty of pharmacy, MTI University, Cairo, Egypt. The term "non-druggable" refers to a protein that cannot be targeted pharmacologically; recently, significant efforts have been made to convert these proteins into targets that are reachable or "druggable." Pharmacologically targeting these difficult proteins has emerged as a major challenge in modern drug development, necessitating the innovation and development of new technologies. The idea of using RNA-targeting therapeutics as a platform to reach unreachable targets is very appealing. Antisense oligonucleotides, nucleic acid or aptamers, RNA interference therapeutics, microRNA, and synthetic RNA are examples of RNA-targeting therapeutics. Many of these agents were FDA-approved for the treatment of rare or genetic diseases, as well as molecular markers for disease diagnosis. As a promising type of therapeutic, many studies are being conducted in order for more and more of them to be approved and used in different disease treatments and to shift them from treating rare diseases only to being used as more specific targeting agents in the treatment of various common diseases. This article will look at some of the most recent technological and pharmaceutical advances that have contributed to the erosion of the concept of undruggability. https://biomedpharmajournal.org/vol14no4/rna-targeting-therapy-a-promising-approach-to-reach-non-druggable-targets/ Antisense Oligonucleotides Aptamers Interference Therapeutics Microrna Synthetic RNA